Table 1.
Summary of survival by patient group (3- and 5-year overall and mediana)
| Patient group | Number of studies | Overall survival (3-year) | Number of studies | Overall survival (5-year) | Number of studies | Mean survival (years) | Median survival (range) |
|---|---|---|---|---|---|---|---|
| All patients | 64 | Mean: 57.6% Median: 57.5% (range 29.7%–80.0%) |
86 | Mean: 40.3% Median: 38.0% (range 16.0%–74.0%) |
61 | 3.8 | 3.6 (1.7–7.3) |
| Solitary CLM | 14 | Mean: 61.0% Median: 66.1% (range 33.4%–79.0%) |
21 | Mean: 47.4% Median: 44.6% (range 27.0%–71.0%) |
14 | 3.6 | 3.6 (1.8–4.8) |
| Extrahepatic CLM | 10 | Mean: 39.8% Median: 43.0% (range 9.0%–75.0%) |
14 | Mean: 23.5% Median: 22.5% (range 0%–48.0%) |
8 | 2.5 | 2.5 (1.4–3.8) |
| Isolated CLM | 10 | Mean: 53.6% Median: 52.5% (range 33.0%–78.0%) |
15 | Mean: 38.5% Median: 38.0% (range 16.0%–73.0%) |
11 | 3.5 | 3.2 (2.5–5.3) |
| Preoperative chemotherapyb | 14 | Mean: 54.6% Median: 52.5% (range 20.8%–79.0%) |
13 | Mean: 36.6% Median: 37.0% (range 7.8%–79.0%) |
16 | 3.2 | 3.3 (1.5–5.2) |
| Initially resectable without the need for chemotherapyc | 12 | Mean: 54.6% Median: 54.8% (range 40.6%–71.0%) |
10 | Mean: 40.7% Median: 38.1% (range 30.0%–68.0%) |
12 | 3.3 | 3.3 (1.9–5.4) |
| Synchronousd | 15 | Mean: 46.3% Median: 46.1% (range 19.3%–81.3%) |
27 | Mean: 36.5% Median: 34.2% (range 11.2%–74.0%) |
16 | 3.1 | 3.2 (1.7–4.2) |
| Metachronous | 14 | Mean: 57.6% Median: 57.8% (range 34.4%–91.0%) |
26 | Mean: 42.6% Median: 41.9% (range 23.0%–73.0%) |
20 | 3.3 | 3.3 (1.5–4.2) |
Notes:
a
Summary of median survival reported or estimated from the studies included, see methods for details on estimation;
b
includes three studies of patients with preoperative chemotherapy only (Gallagher et al,111 Kishi et al,123 Neumann et al84);
c
includes studies that compared preoperative chemotherapy to no preoperative chemotherapy only;
d
one study in synchronous patient populations only (de Santibañes et al105).
Abbreviation: CLM, colorectal cancer liver metastasis.